All In Biotech

Drug Trial Radar · NCT04752813

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 22, 2022

Primary completion

Aug 25, 2026

Study completion Aug 26, 2030

Sponsor

Lead sponsor
BPGbioIndustry
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.

Conditions

  • Glioblastoma
  • Glioblastoma Multiforme

Interventions

  • BPM31510Drug

    Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.

  • Vitamin K1Other

    Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg subcutaneously prior to the beginning of each week of BPM31510 therapy.

  • Temozolomide (TMZ)Drug

    After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for up to 12 cycles post BPM31510 treatment.

  • RadiationRadiation

    After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy will be assessed by subject progression free survivalTime frame: 6 months and 12 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Stanford University Cancer Center

    Palo Alto, California

  • Sansum Clinic

    Santa Barbara, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Valley Health

    Ridgewood, New Jersey

  • Mount Sinai Hospital

    New York, New York

  • Texas Oncology

    Austin, Texas

  • UT Health San Antonio Mays Cancer Center

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Inova

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.